Taiwan Advanced Nanotech

Taiwan Advanced Nanotech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Taiwan Advanced Nanotech (6797.TWO) as of Nov 11, 2026 is 10.33 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 10.66 % — a change of -3.07% (lower).

FCF Conversion

10.33 %

YoY

-3.07%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Taiwan Advanced Nanotech is 2025 10.33 % . FCF Conversion Rate (FCF/EBITDA) of Taiwan Advanced Nanotech was 2024 10.66 % . It decreases by -3.07% lower compared to the previous year.

The Taiwan Advanced Nanotech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
51.69 TWD
Jan 1, 2019
102.35 TWD
Jan 1, 2020
93.10 TWD
Jan 1, 2021
83.56 TWD
Jan 1, 2022
110.27 TWD
Jan 1, 2023
177.67 TWD
Jan 1, 2024
10.66 TWD
Jan 1, 2025
10.33 TWD
The Taiwan Advanced Nanotech FCF Conversion history
YEARFCF ConversionYoY
10.33 %-3.07%
10.66 %-94.00%
177.67 %+61.13%
110.27 %+31.96%
83.56 %-10.24%
93.10 %-9.04%
102.35 %+98.03%
51.69 %-86.68%
388.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Taiwan Advanced Nanotech Stock analysis

What does Taiwan Advanced Nanotech do? Taiwan Advanced Nanotech, Inc. generates revenue through the sale of nucleic acid purification products, including SLA series, Maelstrom series, and LH series instruments designed for DNA/RNA extraction. The company also sells specialized reagents such as virus nucleic acid extraction reagent 665 series, blood nucleic acid extraction reagent 611/61E series, and tissue nucleic acid extraction reagent 6T2/6K2 series. These products are marketed to customers in Taiwan, South Korea, and China, with sales primarily focused on laboratory and medical applications requiring nucleic acid processing. The company's product portfolio targets research institutions, diagnostic laboratories, and healthcare facilities seeking efficient nucleic acid extraction solutions. By offering a range of instruments and reagents tailored to specific extraction needs, Taiwan Advanced Nanotech addresses key segments in the biotechnology and medical diagnostics markets. Sales are distributed across Taiwan, South Korea, and China, reflecting the company's regional market focus. Revenue streams are derived from direct sales of instruments and reagents to end-users in the biotech and healthcare sectors. The SLA, Maelstrom, and LH series instruments serve as core revenue drivers, complemented by recurring reagent sales for ongoing laboratory operations. This dual-product approach ensures steady income from both capital equipment and consumable supplies. Taiwan Advanced Nanotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Taiwan Advanced Nanotech stock

FCF Conversion Rate (FCF/EBITDA) of Taiwan Advanced Nanotech is 10.33 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Taiwan Advanced Nanotech changed from 10.66 % to 10.33 %, representing a -3.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Taiwan Advanced Nanotech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Taiwan Advanced Nanotech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Taiwan Advanced Nanotech

All Key Metrics — Taiwan Advanced Nanotech